Trial record 1 of 64 for:    AIR001
Previous Study | Return to List | Next Study

Long-term Study of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension Who Completed AIR001-CS05

This study has been terminated.
(Terminated early dt acquisition of Sponsor and change in corporate priorities)
Sponsor:
Information provided by (Responsible Party):
Aires Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT01725269
First received: November 8, 2012
Last updated: April 7, 2014
Last verified: April 2014
  Purpose

The AIR001-CS05 study evaluated the safety and efficacy (effectiveness) of AIR001 over 16 weeks in subjects who have PAH. The purpose of the AIR001-CS06 study is to evaluate the intermediate / long-term safety of AIR001 in subjects who have completed the AIR001-CS05 study. Assessments to evaluate the effectiveness of the study drug will include measurements of exercise ability and evaluations of PAH disease symptoms.


Condition Intervention Phase
Pulmonary Arterial Hypertension
Drug: AIR001
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 2, Multicenter, Open-Label Study to Evaluate the Intermediate/Long Term Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension

Resource links provided by NLM:


Further study details as provided by Aires Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • To evaluate the intermediate/long-term safety of inhaled nebulized AIR001 [ Time Frame: minimum of 6 months ] [ Designated as safety issue: Yes ]
    The primary objective of this study is to evaluate the intermediate/long-term safety of inhaled nebulized AIR001 administered according to 3 treatment arms (80 milligrams (mg) 4 times daily, 46 mg 4 times daily, or 80 mg once daily) in subjects with World Health Organization (WHO) Group 1 Pulmonary Arterial Hypertension (PAH) who have completed the 16-week AIR001-CS05 study.


Secondary Outcome Measures:
  • To assess the effect of inhaled AIR001 on Time to Clinical Worsening, 6MWD, Functional Class, and Quality of Life [ Time Frame: minimum of 6 months ] [ Designated as safety issue: Yes ]
    The secondary objectives of this study are to evaluate the effect of inhaled nebulized AIR001 administered according to 3 different treatment arms (80 mg 4 times daily, 46 mg 4 times daily, or 80 mg once daily) in subjects with WHO Group 1 PAH who completed the 16-week AIR001-CS05 study, as determined by time to the first morbidity/mortality event as defined in Time to Clinical Worsening (TTCW) assessments and by change from Baseline in AIR001-CS05 to the 40th week from the start of AIR001 nebulization in AIR001-CS05 (Week 24 of AIR001-CS06) and End of Study (EOS) or Termination visit of AIR001-CS06 in the following:6-Minute Walk Distance (6MWD) assessed at peak, WHO/NYHA Functional Class, Quality of Life (QOL) as measured by SF-36,Borg Dyspnea Index,6MWD assessed at trough


Enrollment: 17
Study Start Date: March 2013
Study Completion Date: April 2014
Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 80mg AIR001, nebulized four times daily
AIR001, 80 mg into nebulizer
Drug: AIR001
All doses specified are the amount loaded into the I-neb AAD System nebulizer.
Other Name: (sodium nitrite inhalation soution)
Experimental: 46 mg AIR001, nebulized four times daily
AIR001, 46 mg into nebulizer
Drug: AIR001
All doses specified are the amount loaded into the I-neb AAD System nebulizer.
Other Name: (sodium nitrite inhalation soution)
Experimental: 80mg AIR001, nebulized once daily
AIR001, 80 mg into nebulizer
Drug: AIR001
All doses specified are the amount loaded into the I-neb AAD System nebulizer.
Other Name: (sodium nitrite inhalation soution)

Detailed Description:

The primary objective of this study is to evaluate the intermediate/long-term safety of inhaled nebulized AIR001 administered according to 3 treatment arms (80 milligrams (mg) 4 times daily, 46 mg 4 times daily, or 80 mg once daily) in subjects with World Health Organization (WHO) Group 1 Pulmonary Arterial Hypertension (PAH) who have completed the 16-week AIR001-CS05 study.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study prior to initiation of any subject-mandated procedures.
  2. Is willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
  3. Has completed the 16-week AIR001-CS05study as planned.
  4. If on corticosteroids, has been receiving a stable dose of less than or equal to 20 mg/day of prednisone (or equivalent dose, if other corticosteroid) for at least 1 month (30 days) prior to the AIR001-CS05 study Baseline/Day 1 visit. If receiving treatment for Connective Tissue Disease (CTD) with any other drugs, doses should remain stable, if clinically feasible, for the duration of the AIR001-CS06 study.
  5. Women of childbearing potential must be using at least one form of medically acceptable contraception (i.e. either oral, topical, implanted hormonal contraceptives, or an intrauterine device) or two barrier methods; have a negative pregnancy test at Screening and Baseline/Day 1 and agree to use reliable methods of contraception until at least 24-hours after the last dose of study drug. Women who are surgically sterile (i.e. hysterectomy, bilateral oophorectomy, or tubal ligation) or those who are post-menopausal for at least 2 years are not considered to be of childbearing potential. Men who are not sterile (i.e. have not had a vasectomy) must also agree to use contraception until at least 24-hours after the last dose of study drug.

Exclusion Criteria:

  1. Participation in a device or other interventional clinical studies (other than AIR001-CS05), within 1 month (30 days) of Baseline/Day 1 and/or during study participation.
  2. Has uncontrolled systemic hypertension as evidenced by sitting systolic blood pressure > 160 mmHg or sitting diastolic blood pressure > 100 mmHg during Baseline/Day 1 visit.
  3. Systolic blood pressure < 90 mmHg at Baseline/Day 1.
  4. Diagnosis of Down syndrome.
  5. Moderate to severe hepatic impairment classified as a Child-Pugh Class B or C at Baseline/Day 1.
  6. Has chronic renal insufficiency as defined by serum creatinine > 2.5 mg/dL or has an estimated Glomerular Filtration Rate (eGFR) < 30 mL/min at Baseline/Day 1, or requires dialytic support.
  7. Has a hemoglobin (Hgb) concentration < 8.5 g/dL at Baseline/Day 1.
  8. Personal or family history of the following:

    1. Congenital or acquired methemoglobinemia;
    2. RBC CYPB5 reductase deficiency.
  9. History of glucose-6-phosphate dehydrogenase (G6PD) deficiency or any contraindication to receiving methylene blue.
  10. For subjects with Human immunodeficiency virus (HIV) associated PAH, requirement for the use of inhaled pentamidine.
  11. The use of oral or topical nitrates (nitroglycerin, glyceryl trinitrate (GTN), isosorbide dinitrate, and isosorbide mononitrate) within 1 month (30 days) prior to Baseline/Day 1 or throughout the AIR001-CS06 study until EOS or Termination visit. Note: Intravenous GTN in an emergency setting may be administered by starting with a low dose and titrating upward, while the subject is being monitored closely for changes in blood pressure and heart rate.
  12. Known or suspected hypersensitivity or allergic reaction to sodium nitrite or sodium nitrate.
  13. History of malignancy within 5-years prior to Baseline/Day 1 of the AIR001-CS05 study, with the exception of localized non-metastatic basal cell carcinoma of the skin and in situ carcinoma of the cervix.
  14. Other severe acute or chronic medical or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
  15. Has a psychiatric, addictive or other disorder that compromises the ability to give informed consent for participating in this study. This includes subjects with a recent history of abusing alcohol or illicit drugs 1 month (30 days) prior to study Baseline/Day 1 of the AIR001-CS05 study and for the duration of the study.
  16. Is currently pregnant or breastfeeding or intends to become pregnant during the duration of the study.
  17. Investigators, study staff or their immediate families.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01725269

  Show 25 Study Locations
Sponsors and Collaborators
Aires Pharmaceuticals, Inc.
Investigators
Principal Investigator: Adaani E Frost, M.D. Baylor College of Medicine, Houston
  More Information

Publications:
Levi, DS, Scott, V, Aboulhosn J. Pulmonary arterial hypertension in congenital heart disease. In: Humbert, M, Lynch, JP, Eds. Pulmonary Hypertension. New York: Informa Healthcare USA, Inc. 2010: 176-195.

Responsible Party: Aires Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT01725269     History of Changes
Other Study ID Numbers: AIR001-CS06
Study First Received: November 8, 2012
Last Updated: April 7, 2014
Health Authority: United States: Food and Drug Administration
European Union: European Medicines Agency
Australia: Department of Health and Ageing Therapeutic Goods Administration

Keywords provided by Aires Pharmaceuticals, Inc.:
AIR001
sodium nitrite
PAH
Pulmonary Arterial Hypertension
inhaled sodium nitrite

Additional relevant MeSH terms:
Hypertension, Pulmonary
Hypertension
Lung Diseases
Respiratory Tract Diseases
Vascular Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on September 16, 2014